Johnson & Johnson filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of the company’s HIV drugs, months after a similar case brought by Gilead Sciences Inc.
Gilead Sciences scored a legal victory regarding fraudulent HIV reimbursements.
An experimental drug being developed by RedHill Biopharma Ltd. that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. Additionally, people living with well-controlled HIV infections are likely to have immune responses to the mRNA COVID-19 vaccines from Moderna and from Pfizer/BioNTech similar to those of otherwise healthy individuals, according to new data.
The World Health Organization said on April 5 it will supply thousands of doses of life-saving antiretroviral drugs to Ukraine to cover the needs of HIV patients in the country for the next 12 months.
The Food and Drug Administration placed a partial hold on CytoDyn’s HIV program and a full clinical hold on the company’s COVID-19 program in the United States.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
Certain drugs used to treat HIV may have a role in preventing SARS-CoV-2 infections, according to preliminary data that may help explain why people living with the condition have not appeared to be at higher risk for serious COVID-19 despite being generally more vulnerable to infections. Additionally, having COVID-19 and influenza at the same time puts hospitalized adults at much greater risk of critical illness and death compared to having COVID-19 without the flu, researchers reported in The Lancet.
ViiV Healthcare and Janssen Pharmaceutical’s Cabenuva treatment for people living with human immunodeficiency virus (HIV-1) received a label update as adult patients now have the option to start the injectable regimen without the need for an oral lead-in period first.
Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574.
The U.S health regulator declined to approve Gilead Sciences’ injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on March 1.